JP7166309B2 - 安定性の良好な医薬組成物 - Google Patents

安定性の良好な医薬組成物 Download PDF

Info

Publication number
JP7166309B2
JP7166309B2 JP2020066699A JP2020066699A JP7166309B2 JP 7166309 B2 JP7166309 B2 JP 7166309B2 JP 2020066699 A JP2020066699 A JP 2020066699A JP 2020066699 A JP2020066699 A JP 2020066699A JP 7166309 B2 JP7166309 B2 JP 7166309B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
dialysis
acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020066699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020169168A (ja
Inventor
良道 牧田
大輔 片岡
和雄 久山
謙司 浅野
僚太郎 芝崎
愛希子 山本
広貴 我妻
敦 鶴田
俊之 鷹橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanwa Kagaku Kenkyusho Co Ltd
EA Pharma Co Ltd
Original Assignee
Sanwa Kagaku Kenkyusho Co Ltd
EA Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanwa Kagaku Kenkyusho Co Ltd, EA Pharma Co Ltd filed Critical Sanwa Kagaku Kenkyusho Co Ltd
Publication of JP2020169168A publication Critical patent/JP2020169168A/ja
Priority to JP2022170262A priority Critical patent/JP7549633B2/ja
Application granted granted Critical
Publication of JP7166309B2 publication Critical patent/JP7166309B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020066699A 2019-04-03 2020-04-02 安定性の良好な医薬組成物 Active JP7166309B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022170262A JP7549633B2 (ja) 2019-04-03 2022-10-25 安定性の良好な医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019071168 2019-04-03
JP2019071168 2019-04-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022170262A Division JP7549633B2 (ja) 2019-04-03 2022-10-25 安定性の良好な医薬組成物

Publications (2)

Publication Number Publication Date
JP2020169168A JP2020169168A (ja) 2020-10-15
JP7166309B2 true JP7166309B2 (ja) 2022-11-07

Family

ID=72667705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020066699A Active JP7166309B2 (ja) 2019-04-03 2020-04-02 安定性の良好な医薬組成物
JP2022170262A Active JP7549633B2 (ja) 2019-04-03 2022-10-25 安定性の良好な医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022170262A Active JP7549633B2 (ja) 2019-04-03 2022-10-25 安定性の良好な医薬組成物

Country Status (8)

Country Link
US (1) US20220142958A1 (enExample)
EP (1) EP3950058A4 (enExample)
JP (2) JP7166309B2 (enExample)
KR (1) KR20210146280A (enExample)
CN (1) CN113260416A (enExample)
BR (1) BR112021013002A2 (enExample)
CA (1) CA3124687A1 (enExample)
WO (1) WO2020204117A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117247339B (zh) * 2023-11-16 2024-03-12 潍坊富邦药业有限公司 一种烷基胺衍生物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013063971A (ja) 2011-09-02 2013-04-11 Ajinomoto Co Inc アルキルアミン誘導体を有効成分とする医薬
WO2014119643A1 (ja) 2013-01-31 2014-08-07 千寿製薬株式会社 澄明な水性液剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4154900B1 (en) 2009-07-29 2024-08-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
ES2712048T3 (es) * 2010-03-04 2019-05-09 Ea Pharma Co Ltd Derivado de alquilamina
WO2011108724A1 (ja) * 2010-03-04 2011-09-09 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
CN107614486A (zh) * 2015-06-01 2018-01-19 味之素株式会社 烷基胺衍生物的制造方法及其制造中间体
CN109200024A (zh) * 2017-07-07 2019-01-15 江苏恒瑞医药股份有限公司 西那卡塞药物组合物及其医药用途
TWI859130B (zh) * 2017-12-20 2024-10-21 日商Ｅａ製藥股份有限公司 維持透析下之二次性副甲狀腺機能亢進症之預防或治療用醫藥組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013063971A (ja) 2011-09-02 2013-04-11 Ajinomoto Co Inc アルキルアミン誘導体を有効成分とする医薬
WO2014119643A1 (ja) 2013-01-31 2014-08-07 千寿製薬株式会社 澄明な水性液剤

Also Published As

Publication number Publication date
US20220142958A1 (en) 2022-05-12
JP2022186861A (ja) 2022-12-15
BR112021013002A2 (pt) 2021-10-13
CN113260416A (zh) 2021-08-13
JP2020169168A (ja) 2020-10-15
EP3950058A1 (en) 2022-02-09
EP3950058A4 (en) 2023-01-04
WO2020204117A1 (ja) 2020-10-08
CA3124687A1 (en) 2020-10-08
JP7549633B2 (ja) 2024-09-11
KR20210146280A (ko) 2021-12-03

Similar Documents

Publication Publication Date Title
US11357855B2 (en) Liquid formulation
JP6510136B1 (ja) 維持透析下の二次性副甲状腺機能亢進症の予防または治療用医薬組成物
US20230135366A1 (en) Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products
JP7549633B2 (ja) 安定性の良好な医薬組成物
US20260103497A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
HK40052036A (en) Pharmaceutical composition having favorable stability
HK40066239A (en) Pharmaceutical composition having favorable stability
CA3085706C (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
KR20190087039A (ko) 리세드론산 또는 그의 염 및 비타민d를 함유하는 경구용 에멀젼 조성물 및 그 제조방법
CA3268560A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
HK40031634B (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
HK40031634A (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
HK40027549A (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
HK1208372B (en) Liquid formulation

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20200428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221025

R150 Certificate of patent or registration of utility model

Ref document number: 7166309

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250